Preliminary Three-Year SIRONA Data Presented by Concept Medical at Charing Cross Symposium 2026

Groundbreaking Data Presented at Charing Cross Symposium 2026

Concept Medical Inc. recently unveiled compelling preliminary data from a three-year follow-up of the SIRONA randomized trial during the Charing Cross Symposium 2026 in London. As leaders in drug delivery technologies for peripheral interventions, Concept Medical's findings mark a significant leap in patient care and treatment efficacy.

The SIRONA trial explores the effectiveness of sirolimus-coated balloons in arterial interventions, specifically comparing this innovative approach against the conventional paclitaxel-coated balloons. The necessity for this trial is underscored by the historical reliance on paclitaxel therapies, which have dominated the market but come with considerable complications and limitations. The intrigue surrounding these findings lies not only within their statistical robustness but also in their implications for future patient care.

In a presentation led by Principal Investigator Professor Ulf Teichgräber, the data revealed that the MagicTouch PTA, a sirolimus-coated balloon, demonstrated impressive long-term outcomes. Specifically, the study showed a notable reduction in clinically indicated target lesion revascularization (cdTLR). After three years, cdTLR rates were 88.2% for the sirolimus cohort versus 80.2% for the paclitaxel group. The hazard ratio of 0.60 indicates a compelling advantage for the sirolimus technology, with a p-value of 0.03 demonstrating statistical significance.

The findings also maintained a reassuring safety profile, as overall mortality and major amputation rates were comparable between both treatment groups. The absence of all-cause mortality sat at 92.6% across the board, and major amputation rates remained exceedingly low at 99.6% for both modalities—underscoring the potential of sirolimus in interventions related to peripheral arterial disease.

Professor Teichgräber expressed his optimism during the session, highlighting that the sustained decrease in cdTLR is a promising indicator of the durability of sirolimus-based therapies in femoropopliteal interventions. He further stressed the importance of approaching such data with caution, indicating that these results should not be generalized across all sirolimus technologies without thorough clinical evaluation. Each treatment modality must stand independently based on robust evidence to ensure patient safety and care outcomes.

Adding to the enthusiasm, Dr. Manish Doshi, founder and CEO of Concept Medical, elaborated on the study's long-term vision. He remarked, “The SIRONA trial is a perfect embodiment of our commitment to long-term clinical science, aiming not just for initial results but for tangible durational evidence that physicians can trust.” This emphasis on quality data will be vital as Concept Medical continues to expand its global footprint and aims to further revolutionize vascular intervention methodologies.

Concept Medical Inc. has established itself as a pioneering force in drug delivery technologies for vascular interventions, with its headquarters located in Florida and manufacturing operations in India. Their patented Nanolute™ platform facilitates sustained release and controlled delivery of sirolimus, positioning MagicTouch as one of the most clinically studied sirolimus-coated balloon technologies worldwide.

As these findings from the SIRONA trial await confirmation from the Clinical Events Committee, the initial data signals a promising new direction for treating peripheral arterial disease—a feat likely to enhance patient quality of life and management in the coming years.